Publication | Open Access
Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
57
Citations
0
References
2017
Year
Keynote-028 StudyPancreatic CancerMedicinePharmacologyPathologyPancreatic Neuroendocrine TumorsImmune Checkpoint InhibitorCancer TreatmentPd-l1–positive Advanced CarcinoidOncologyRadiation OncologyMolecular Oncology
No additional data available for this publication yet. Check back later!